Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.7 USD | -0.14% |
|
-3.91% | +17.15% |
Jul. 01 | Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat | MT |
Jul. 01 | Merck: license agreement with Orion Corp. for opevesostat | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.15% | 324B | B- | ||
+55.55% | 823B | C+ | ||
+42.31% | 641B | B | ||
-6.83% | 352B | C+ | ||
+7.09% | 301B | C+ | ||
+14.02% | 241B | B+ | ||
+1.64% | 223B | A+ | ||
+13.66% | 218B | B- | ||
+7.87% | 167B | C+ | ||
-3.33% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck & Co., Inc.